Form 990 for tax year 2022
Filed by FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND.
Totals
- Total revenue
- $144,248,069
- Total expenses
- $146,186,498
- Contributions and grants received
- $142,991,509
- Grants paid
- $87,636,841
- Program service revenue
- $0
- Investment income
- $961,319
- Other revenue
- $295,241
- Total assets, end of year
- $137,542,319
- Total liabilities, end of year
- $115,874,802
- Net assets or fund balances, end of year
- $21,667,517
- Program services expenses (Part IX)
- $135,321,873
- Management and general expenses
- $10,058,716
- Fundraising expenses
- $805,909
- Program service expenses (Part III)
- $135,321,873
Program services were 92.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1e · Government grants (contributions)
$118,426,164
-
1f · All other contributions, gifts and grants
$24,565,345
-
3 · Investment income
total $961,319 · excluded $961,319
-
4 · Income from investment of tax-exempt bond proceeds
total $0
-
5 · Royalties
total $0
-
6c · Rental income or loss
real property $0 · personal property $0
-
6d · Net rental income or loss
total $0
-
7d · Net gain or loss
total $0
-
8a · Fundraising events: gross income
$0
-
8b · Fundraising events: direct expenses
$0
-
8c · Net income from fundraising events
total $0
-
9a · Gaming: gross income
$0
-
9b · Gaming: direct expenses
$0
-
9c · Net income from gaming
total $0
-
10a · Gross sales of inventory
$0
-
10b · Cost of goods sold
$0
-
10c · Net income from sales of inventory
total $0
-
11a · Other revenue: COMMISSION ON TAX DEDUCTION
total $35,133 · excluded $35,133
-
11b · Other revenue: OTHER INCOME
total $260,108 · excluded $260,108
-
11e · Other revenue, total
$295,241
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $17,751,551 · program services $17,751,551
-
2 · Grants to domestic individuals
total $0
-
3 · Grants to foreign organizations and individuals
total $69,885,290 · program services $69,885,290
-
4 · Benefits paid to or for members
total $0
-
5 · Compensation of officers, directors and key employees
total $2,467,485 · program services $1,550,803 · management and general $751,482 · fundraising $165,200
-
6 · Compensation of disqualified persons
total $0
-
7 · Other salaries and wages
total $15,627,720 · program services $12,300,226 · management and general $3,095,379 · fundraising $232,115
-
8 · Pension plan contributions
total $1,381,101 · program services $1,041,902 · management and general $329,343 · fundraising $9,856
-
9 · Other employee benefits
total $925,049 · program services $553,348 · management and general $362,165 · fundraising $9,536
-
10 · Payroll taxes
total $1,514,784 · program services $1,173,415 · management and general $317,325 · fundraising $24,044
-
11a · Fees: management
total $1,269,424 · program services $459,351 · management and general $810,073
-
11b · Fees: legal
total $79,120 · program services $3,787 · management and general $75,333
-
11c · Fees: accounting
total $320,359 · program services $144,228 · management and general $176,131
-
11d · Fees: lobbying
total $0
-
11e · Fees: professional fundraising services
total $0
-
11f · Fees: investment management
total $0
-
11g · Fees: other
total $14,785 · program services $314 · management and general $14,471
-
12 · Advertising and promotion
total $0
-
13 · Office expenses
total $1,758,474 · program services $1,706,948 · management and general $51,526
-
14 · Information technology
total $1,936,196 · program services $1,346,149 · management and general $590,047
-
15 · Royalties
total $0
-
16 · Occupancy
total $955,401 · program services $16,997 · management and general $938,404
-
17 · Travel
total $2,329,044 · program services $2,071,757 · management and general $227,403 · fundraising $29,884
-
18 · Travel or entertainment for public officials
total $0
-
19 · Conferences, conventions and meetings
total $403,211 · program services $307,968 · management and general $95,243
-
20 · Interest
total $0
-
21 · Payments to affiliates
total $0
-
22 · Depreciation, depletion and amortization
total $4,461 · management and general $4,461
-
23 · Insurance
total $83,374 · program services $11,995 · management and general $71,379
-
24a · Other expenses: PROJECT CONTRACTORS
total $19,812,475 · program services $18,427,047 · management and general $1,050,154 · fundraising $335,274
-
24b · Other expenses: EQUIPMENT & SUPPLIES
total $6,687,856 · program services $6,525,392 · management and general $162,464
-
24c · Other expenses: TRANSLATION & SPONSORSHIP
total $69,170 · program services $43,405 · management and general $25,765
-
24d · Other expenses: FOREIGN EXCHANGE LOSSES
total $910,168 · management and general $910,168
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $22,817,170 · end of year $39,489,542
-
2 · Savings and temporary cash investments
beginning of year $123,146,860 · end of year $81,401,662
-
3 · Pledges and grants receivable
beginning of year $0 · end of year $0
-
4 · Accounts receivable
beginning of year $13,930,408 · end of year $7,215,019
-
5 · Loans and receivables from officers and key people
beginning of year $0 · end of year $0
-
6 · Loans and receivables from disqualified persons
beginning of year $0 · end of year $0
-
7 · Other notes and loans receivable
beginning of year $0 · end of year $0
-
8 · Inventories for sale or use
beginning of year $0 · end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $29,389,709 · end of year $9,166,796
-
10a · Land, buildings and equipment: cost or other basis
$76,320
-
10b · Land, buildings and equipment: accumulated depreciation
$76,320
-
10c · Land, buildings and equipment, net
beginning of year $4,461 · end of year $0
-
11 · Investments: publicly traded securities
beginning of year $0 · end of year $0
-
12 · Investments: other securities
beginning of year $0 · end of year $0
-
13 · Investments: program-related
beginning of year $0 · end of year $0
-
14 · Intangible assets
beginning of year $0 · end of year $0
-
15 · Other assets
beginning of year $218,509 · end of year $269,300
-
17 · Accounts payable and accrued expenses
beginning of year $9,499,354 · end of year $19,116,387
-
18 · Grants payable
beginning of year $0 · end of year $0
-
19 · Deferred revenue
beginning of year $157,963,445 · end of year $96,758,415
-
20 · Tax-exempt bond liabilities
beginning of year $0 · end of year $0
-
21 · Escrow or custodial account liability
beginning of year $0 · end of year $0
-
22 · Loans and payables to officers and key people
beginning of year $0 · end of year $0
-
23 · Secured mortgages and notes payable
beginning of year $0 · end of year $0
-
24 · Unsecured notes and loans payable
beginning of year $0 · end of year $0
-
25 · Other liabilities
beginning of year $0 · end of year $0
-
27 · Net assets without donor restrictions
beginning of year $6,008,808 · end of year $12,607,693
-
28 · Net assets with donor restrictions
beginning of year $16,035,510 · end of year $9,059,824
Mission and programs · 2022
Mission
FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.
Activities or mission (Part I)
The development and implementation of new, low cost diagnostics for infectious diseases for use in low- resource areas.
-
COVID-19 EXPENDITURE USD 103,061,587 FIND's 2022 COVID-19 activities addressed access inequities as well as diagnostics research and development (R&D). FIND led major advances in regional diagnostics manufacturing and evaluated more than 50 COVID-19 tests. Investments led directly to manufacturing capacity based in low- and middle-income countries (LMICs) of 60 million COVID-19 rapid tests (RDTs) and self-tests per month, available to LMICs at US$1-2 per test. FIND's technology transfer programmes enabled Diatropix (Senegal) to manufacture high-quality COVID-19 RDTs and break ground on a new facility for low-cost, high-volume manufacturing for RDTs of regional importance. FIND supported Premier Medical Corporation (India) to expand production capacity to 10 million RDTs/month under global access terms. FIND enabled WAMA Diagnstica (Brazil) in the end-to-end manufacture of RDTs from raw materials. FIND's support enabled Wondfo Biotech (China) and Viatris (South Africa) to achieve WHO Emergency Use Listing (EUL) for their COVID-19 RDTs. Additionally, FIND's provision of independent trial data supported the WHO Emergency Use Listing (EUL) of six COVID-19 tests in 2022, and a seventh in 2023. FIND's assessment of COVID-19 Ag RDT performance included test accuracy and the ability to detect new variants. These studies have now encompassed 54 Ag RDTs, including professional use and self-tests. FIND monitored and mapped both testing and sequencing capacity for COVID-19, as well as tracking the impact of new variants of concern on test performance. FIND supported decentralized community-based testing for COVID-19 and test-and-treat strategies. FIND also generated data that helped in-country policy reviews on the use of Ag RDTs in settings beyond those recommended in the WHO guidelines, including pharmacy channels and non-traditional settings such as taxi ranks. FIND supported the procurement of 1,889,144 diagnostic tests and related consumables, of which 1,853,854 were COVID-19 Ag RDTs, while supporting the introduction of their use in 26 countries.
Expenses $103,061,587 · Grants $72,311,140
-
Tuberculosis (TB) and hepatitis (HCV) EXPENDITURE USD 10,283,492 FIND initiated its first-ever comprehensive involvement of patients in study design, through the Unitaid-funded DriveDx4TB project to seek patient perspectives on novel sample types for TB diagnostics. In the recent development of a WHO target product profile (TPP) for TB, FIND developed an impact model that indicates that new point-of-care (POC) tests for TB that provide results to the patient during the same clinical visit would require minimum sensitivities of 59-70% and 65-71% for non-sputum and sputum samples, respectively, depending on the country and standard of care, to achieve comparable or better case detection than the current standard of care. To maximize value for money of newly developed TB diagnostics, FIND introduced evidence-based target pricing into the forthcoming TPP for TB diagnostics. This work provides a novel framework to guide the future development of TPPs for diagnostics. FIND supported 10 TB products (7 IVDs and 3 digital tools) across various stages of diagnostic product life cycle including 4 IVDs and 1 digital tool in the development phases. FIND also supported 3 HCV tests in the development phases. FIND led the development of targeted next-generation sequencing (tNGS) for use in patients with TB, and the data obtained from this three-country study form the backbone of a new WHO evidence review and guidelines for TB management. FIND identified and demonstrated lot-to-lot variability of the FujiLAM TB rapid test as an unanticipated outcome of a large, seven-country evaluation of the test's accuracy, supporting the WHO decision to cancel a policy review; FIND supported FujiFilm in conducting a root cause analysis and planning a redesigned test. An existing digital global good, developed by MedicMobile, was enhanced to allow for bidirectional TB and COVID-19 screening and NCD screening.
Expenses $10,283,492 · Grants $3,528,906
-
Access EXPENDITURE USD 6,560,663 FIND and the Indonesian Ministry of Health (MoH) signed a memorandum of understanding (MoU) to expand access to essential diagnostics across 18,000 primary health centres throughout Indonesia, while enhancing pandemic surveillance and advancing diagnostics manufacturing in Indonesia. FIND entered a collaboration with the African Society for Laboratory Medicine (ASLM) and jointly launched the diagnostic network optimization sub-community of practice (DNO subCoP), under the overarching laboratory systems strengthening community of practice (LabCoP) initiative. Out of a target of 15 countries, 12 countries have ongoing or completed analyses using OptiDx-network optimization software co-developed by FIND to support resource planning for national laboratory systems-for TB, TB/HIV, and associated molecular testing. The capacity building of country teams in the use of OptiDx continues in several countries, including Cote d'Ivoire, India, and Zambia. Two strategic DNO analyses are underway, in Kenya and Pakistan, which will likely inform key priorities, including planning for Global Fund support, and integrated disease testing. FIND also developed an online DNO course, aimed at strategic decision-makers, in which 393 participants from 30 countries participated. DNO analyses in countries have focused on identifying gaps in testing capacity and strategies needed to expand testing in hard-to-reach areas.
Expenses $6,560,663 · Grants $3,736,744
As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
William Rodriguez
Chief Executive Officer
- Total calculated
- $421,585
- From this org
- $323,816
- From related orgs
- $0
- Other
- $97,769
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $308,730
- Bonus
- $15,086
- Other
- $0
- Deferred
- $67,143
- Nontaxable benefits
- $30,626
- Filer's total
- $421,585
-
Sergio CarmonaSERGIO CARMONA
CHIEF MEDICAL OFFICER
- Total calculated
- $392,367
- From this org
- $328,189
- From related orgs
- $0
- Other
- $64,178
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $319,622
- Bonus
- $8,567
- Other
- $0
- Deferred
- $60,016
- Nontaxable benefits
- $4,162
- Filer's total
- $392,367
-
Louisa ChaubertLOUISA CHAUBERT
Director of Finance
- Total calculated
- $330,220
- From this org
- $270,419
- From related orgs
- $0
- Other
- $59,801
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $261,852
- Bonus
- $8,567
- Other
- $0
- Deferred
- $53,506
- Nontaxable benefits
- $6,295
- Filer's total
- $330,220
-
Emma Jane Hannay
Chief Access Officer
- Total calculated
- $309,104
- From this org
- $254,174
- From related orgs
- $0
- Other
- $54,930
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $245,553
- Bonus
- $8,621
- Other
- $0
- Deferred
- $54,930
- Nontaxable benefits
- $0
- Filer's total
- $309,104
-
Willo Brock start 922
VP,external Affairs
- Total calculated
- $301,537
- From this org
- $273,739
- From related orgs
- $0
- Other
- $27,798
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $262,155
- Bonus
- $11,584
- Other
- $0
- Deferred
- $22,213
- Nontaxable benefits
- $5,585
- Filer's total
- $301,537
-
Daniel Bausch
sr. advisor, global health sec
- Total calculated
- $291,827
- From this org
- $231,901
- From related orgs
- $0
- Other
- $59,926
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $223,334
- Bonus
- $8,567
- Other
- $0
- Deferred
- $48,289
- Nontaxable benefits
- $11,637
- Filer's total
- $291,827
-
Marta Fernandez Suarez
Chief Technology Officer
- Total calculated
- $288,781
- From this org
- $252,721
- From related orgs
- $0
- Other
- $36,060
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $242,005
- Bonus
- $10,716
- Other
- $0
- Deferred
- $20,461
- Nontaxable benefits
- $15,599
- Filer's total
- $288,781
-
Morten RuhwaldMORTEN RUHWALD
Director, TB Programme
- Total calculated
- $283,058
- From this org
- $230,800
- From related orgs
- $0
- Other
- $52,258
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $219,431
- Bonus
- $11,369
- Other
- $0
- Deferred
- $42,050
- Nontaxable benefits
- $10,208
- Filer's total
- $283,058
-
Sharon SaacksSHARON SAACKS
DIRECTOR OF OPERATIONS
- Total calculated
- $277,715
- From this org
- $219,034
- From related orgs
- $0
- Other
- $58,681
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $210,467
- Bonus
- $8,567
- Other
- $0
- Deferred
- $47,288
- Nontaxable benefits
- $11,393
- Filer's total
- $277,715
-
Beatrice MoutonBEATRICE MOUTON
Director, Human Resources
- Total calculated
- $266,716
- From this org
- $224,498
- From related orgs
- $0
- Other
- $42,218
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $215,931
- Bonus
- $8,567
- Other
- $0
- Deferred
- $42,218
- Nontaxable benefits
- $0
- Filer's total
- $266,716
-
Stefano OngarelloSTEFANO ONGARELLO
Director, Data Science
- Total calculated
- $256,743
- From this org
- $207,805
- From related orgs
- $0
- Other
- $48,938
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $201,647
- Bonus
- $6,158
- Other
- $0
- Deferred
- $39,505
- Nontaxable benefits
- $9,433
- Filer's total
- $256,743
-
Sylvain BielerSYLVAIN BIELER
Senior Scientist
- Total calculated
- $253,990
- From this org
- $213,699
- From related orgs
- $0
- Other
- $40,291
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $205,385
- Bonus
- $8,314
- Other
- $0
- Deferred
- $40,291
- Nontaxable benefits
- $0
- Filer's total
- $253,990
-
Sanjay Sarin
VP, ACCESS
- Total calculated
- $236,562
- From this org
- $236,562
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $228,000
- Bonus
- $8,562
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $236,562
-
Aditi Srinivasan
Director, Data Science
- Total calculated
- $233,937
- From this org
- $203,387
- From related orgs
- $0
- Other
- $30,550
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $198,511
- Bonus
- $4,876
- Other
- $0
- Deferred
- $30,550
- Nontaxable benefits
- $0
- Filer's total
- $233,937
-
Cassandra Kelly-Cirinostart922
VP; Health Programmes
- Total calculated
- $97,076
- From this org
- $76,930
- From related orgs
- $0
- Other
- $20,146
- Hours/week
- 40
-
MARK KESSEL end 1122
CHAIRMAN OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Daniel Robert CamusDANIEL ROBERT CAMUS
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
ANDREW JOHN JACK end 1122
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Iona KickbushIONA KICKBUSH
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Carlos Morel MedicisCARLOS MOREL MEDICIS
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Marcel TannerMARCEL TANNER
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
SHEILA TLOU end 922
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
MICHAEL WATSON end 922
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
David HeymannDAVID HEYMANN
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
GAO FU end 922
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Kamineni ShobanaKAMINENI SHOBANA
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Frutiger ChristianFRUTIGER CHRISTIAN
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 1
-
Ayoade Alakija start 1122
Chairman of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Soumya Swaminathanstart1122
Member of the Board
- Total calculated
- $0
- Hours/week
- 1
-
Precious Matsoso start 1122
member of the board
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
Biomeme
$4,015,000
Development of diagnostic tests
-
Transnational TechnologiesInc
$3,200,000
Supportmanufacturingandcommercializationof antigenrdtforcovid
-
WHO-PAHO
$2,275,676
Scaling-uptheuseofcovidantigenrapiddiagnost ic tests in Americas testsinAmericas testsinAmericas
-
CHAI-ClintonHealthAccessInitiationInc
$2,007,458
TosupportTBeliminationefforts
-
DiagnosticConsultingNetworkInc
$854,249
Developmentofdiagnostictests
-
Elizabeth Glaser Pediatric Aids Foundation
$793,500
Evaluation of Antigen Rapid Diagnostic Tests
-
$792,000
ImplementationofcovidagRDTsinSouthSudan
-
$655,323
Sponsored Research
-
$644,191
Laboratorystrengtheningtosupportclinicalcare andresearch
-
ManagementSciencesforHealth
$621,481
Undertake a project in the field of in vitro diagnostics and COVID
The 10 largest by cash amount. The API serves every itemized grant.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 3
- Employees, agents and contractors (line 3c)
- 129
- Expenditures and investments (line 3c)
- $122,280,114
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| Sub-Saharan Africa | 1 | 4 | Program Services | SEE PART V | $24,292,340 |
| South Asia | 0 | 2 | Program Services | See Part V | $5,423,718 |
| East Asia and the Pacific | 1 | 7 | Program Services | See Part V | $22,172,364 |
| Europe (Including Iceland and Greenland) | 1 | 116 | Program Services | See Part V | $63,637,622 |
| South America | 0 | 0 | Program Services | See Part V | $3,774,608 |
| North America | 0 | 0 | Program Services | See Part V | $676,041 |
| Russia and the Newly Independent States | 0 | 0 | Program Services | See Part V | $1,246,649 |
| Middle East and North Africa | 0 | 0 | Program Services | See Part V | $251,485 |
| Central America and the Caribbean | 0 | 0 | Program Services | See Part V | $805,287 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| Sub-Saharan Africa | $17,684,107 | ELEC FD TRAN | — | N/A | N/A |
| South Asia | $1,937,978 | ELEC FD TRAN | — | N/A | N/A |
| East Asia and the Pacific | $18,066,911 | ELEC FD TRAN | — | N/A | N/A |
| Europe (Including Iceland and Greenland) | $26,938,776 | ELEC FD TRAN | — | N/A | N/A |
| South America | $3,331,496 | ELEC FD TRAN | — | N/A | N/A |
| North America | $215,853 | ELEC FD TRAN | — | N/A | N/A |
| Russia and the Newly Independent States | $903,809 | ELEC FD TRAN | — | N/A | N/A |
| Middle East and North Africa | $43,893 | ELEC FD TRAN | — | N/A | N/A |
| Central America and the Caribbean | $762,468 | ELEC FD TRAN | — | N/A | N/A |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 131
- Other grantees (Part II line 3)
- 217
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
FIND INDIA
n/a · PROGRAM SVCS · IN · controlled entity
Directly controlled by FIND SWISS
-
FIND DX NPC
n/a · PROGRAM SVCS · SF · controlled entity
Directly controlled by FIND SWISS
-
FIND DX KENYA
n/a · PROGRAM SVCS · KE · controlled entity
Directly controlled by FIND SWISS
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 15 November 2023
- IRS schema version
- 2022v5.0
- Source object
- 202343199349316034
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.